FDA New Drug Approvals
Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-23-NI-03Mar 7, 2023
Marketing Authorization
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis
Pfizer
PR-M08-18-NI-024Aug 7, 2018